Introduction
============

Cough is a respiratory defense mechanism to protect our body from external materials, such as dust and pathogens. However, persistent and uncontrollable cough can affect the patients' quality of life by inducing nausea and sleep disturbance.[@b1-dddt-12-1413] To relieve cough, levodropropizine is one of the therapeutic options used to treat acute and chronic bronchitis.[@b2-dddt-12-1413] Levodropropizine is a peripherally acting, non-opioid antitussive agent, which inhibits the cough reflex by reducing the release of sensory peptide in the peripheral region and suppresses the afferent pathway of pulmonary.[@b3-dddt-12-1413]--[@b5-dddt-12-1413] It has comparable efficacy and less central sedative adverse effects compared to the centrally acting antitussives.[@b1-dddt-12-1413] Levodropropizine has been approved in some Asian and European countries and has been widely used for adults and children older than 2 years in Republic of Korea.

Levodropropizine is rapidly absorbed into the gastrointestinal tract, with time required to reach the maximum drug concentration (*T*~max~) ranging from 0.25 to 0.75 h.[@b6-dddt-12-1413] This absorption profile is due to high bioavailability (\>75%) and rapid distribution of levodropropizine.[@b7-dddt-12-1413] The mean terminal half-life (*t*~1/2~) of levodropropizine is 2.73 h, which suggests rapid elimination after systemic absorption. Levodropropizine has linear pharmacokinetic (PK) characteristics at doses ranging from 30 to 90 mg.[@b8-dddt-12-1413] The effects of food on the PK characteristics of levodropropizine have not been evaluated yet.

The food intake can change the systemic exposure of drug by altering the absorption and/or elimination of drug. For instance, food can alter either the gastric emptying time or pH conditions of the gastrointestinal tract, which can affect the absorption kinetics of the drug. The dietary intake can also change the elimination profile of the drug by increasing the blood flow and by stimulating the bile production.[@b9-dddt-12-1413],[@b10-dddt-12-1413] Especially in the case of a sustained release drug, it is necessary to evaluate the interaction between food and drug, since the patients are more likely to consume food during the dosing interval.

The currently available dosage forms of levodropropizine worldwide are syrup, capsule, and tablet. The levodropropizine immediate-release (IR) tablet 60 mg is prescribed three times daily (a total daily dose of 180 mg) for adults. To improve the dosing convenience and patients' compliance, levodropropizine controlled-release (CR) tablet is under development by Korea United Pharm Inc. (Seoul, Republic of Korea).[@b11-dddt-12-1413]--[@b13-dddt-12-1413]

The aim of this study is to compare the PK profiles of CR and IR formulations of levodropropizine in the fasted state. In addition, the effects of food on the PK of levodropropizine CR formulation in healthy male subjects are evaluated.

Subjects and methods
====================

Subjects
--------

Korean male subjects aged 20--55 years, who were evaluated as healthy based on medical history, 12-lead electrocardiography, vital signs, physical examination, and clinical laboratory tests, were enrolled in this study. Subjects were determined healthy if they had none of the following medical histories: known hypersensitivity to levodropropizine or other antitussive agent and a history of cardiovascular, respiratory, renal, metabolic, hematologic, gastrointestinal, neurologic, psychiatric, oncologic, or hepatic disease. All subjects provided a written informed consent before participating in the study. This clinical study (Clinical Research Information Service registration number: KCT0002383) was approved by the institutional review board (IRB) of Chungnam National University Hospital (IRB number: CNUH 2011-12-019) and was conducted in accordance with the Declaration of Helsinki as implemented in the Good Clinical Practice guidelines.

Study design
------------

A randomized, open-label, multiple-dose, three-treatment, three-period, six-sequence Williams design crossover study was conducted. The randomization was performed using the PROC PLAN procedure of SAS^®^ software. Subjects were randomly assigned to one of the six treatment sequences, which involve combinations of the following three treatments: levodropropizine IR 60 mg three times daily with 6-h interval in the fasted state, levodropropizine CR 90 mg two times daily with 12-h interval in the fasted state, and levodropropizine CR 90 mg two times daily with 12-h interval in the fed state ([Figure 1](#f1-dddt-12-1413){ref-type="fig"}). The total daily dose of levodropropizine was 180 mg in all treatment groups. For the fasted groups, at least 10 h of fasted state were required prior to drug administration. For the fed group, subjects received high-fat meal (946 kcal; fat content, 35.5%) prior to drug administration. One-week washout period was set between the different treatment periods based on the *t*~1/2~ of levodropropizine. For PK analysis of levodropropizine IR, blood samples were obtained at 0, 0.25, 0.5, 0.75, 1, 2, 4, 6, 6.25, 6.5, 6.75, 7, 8, 10, 12, 12.25, 12.5, 12.75, 13, 14, 16, 18, and 24 h post-dose. For levodropropizine CR, serial blood samples were collected at 0, 0.25, 0.5, 0.75, 1, 2, 4, 6, 8, 12, 12.25, 12.5, 12.75, 13, 14, 16, 18, and 24 h post-dose.

Determination of levodropropizine plasma concentrations
-------------------------------------------------------

The blood samples were centrifuged at 3,000 rpm for 10 min at 4°C, and the plasma samples were stored at −70°C until assay. Plasma concentrations of levodropropizine were determined by using high-performance liquid chromatography (1260 series; Agilent Technologies, Santa Clara, CA, USA) coupled with a mass spectrometer (6410A Triple quad mass spectrometer; Agilent Technologies). The blood samples were treated with acetonitrile for precipitation of proteins, and terazosin was used as an internal standard (IS) for quantitation of levodropropizine. Levodropropizine was separated on an Eclipse XDB-C18 column (3.0 × 100 mm, 3.5 μm; Agilent Technologies) and detected using the positive electrospray ionization and multiple reaction monitoring modes. The mobile phase consisted of 0.2% formic acid in 5 mM ammonium formate and acetonitrile (40:60, v/v), and the flow rate was 0.35 mL/min. The lower limit of quantification (LLOQ) was 5 ng/mL, and the calibration curve for levodropropizine was linear over the range of 5--1,000 ng/mL with a coefficient of determination of ≥0.99. The intraday and interday precision were ≤3.6 and ≤6.7%, respectively. The intraday and interday accuracy ranged from 95.3 to 103.5% and 98.2 to 99.2%, respectively.

PKs and statistical analysis
----------------------------

The PK parameters were calculated through a non-compartmental analysis using Phoenix^®^ WinNonlin^®^ software version 1.4 (Certara, St Louis, MO, USA). To compare the total exposure to levodropropizine CR and IR, the maximum plasma concentration (*C*~max~) and area under the concentration--time curve from the 0 to 24 h time points (AUC~0--24h~) were calculated. In addition, to determine the PK parameters of levodropropizine IR, the 0--6 h data were used because they represent the data set after the first dose. Similarly, to determine the PK parameters of levodropropizine CR, the 0--12 h data were used. The following PK parameters were calculated for both levodropropizine IR and CR: *C*~max~, *T*~max~, AUC from 0 to dose interval time (AUC~0--tau~), AUC from 0 to infinity (AUC~inf~), *t*~1/2~, and apparent clearance (CL/F). The AUC was calculated using the linear trapezoidal--linear interpolation method. The *T*~max~ and *C*~max~ were determined directly based on the observed values. The values below the LLOQ prior to the *T*~max~ were regarded as 0, and the values after the *T*~max~ were regarded as missing data. No imputations were made for the missing data when calculating PK parameters.

Statistical analyses were performed using SAS^®^ software version 6.4 (SAS Institute Inc., Cary, NC, USA). A mixed-effects analysis of variance (ANOVA) model was fit by using the natural logarithm-transformed *C*~max~ and AUC~0--24h~. Based on the ANOVA model, PK comparisons between different formulations were assessed by calculating the geometric mean ratio (GMR) and 90% confidence interval (90% CI) of levodropropizine CR to IR for the *C*~max~ and AUC~0--24h~. In addition, to evaluate the food effect on the PK of levodropropizine CR, the GMR and 90% CI of the fed group to the fasted group for the C~max~ and AUC~0--24h~ were calculated. Furthermore, the GMR and 90% CI of AUC~0--tau~/D and AUC~inf~/D were calculated. The ANOVA test was used to determine the statistical difference in demographic baseline between six sequences.

Tolerability assessment
-----------------------

Tolerability was evaluated in all subjects who received at least one dose of the study drug throughout the entire study period. Tolerability was evaluated based on the assessment of the vital signs (blood pressure, heart rate, and body temperature), physical examination, 12-lead electrocardiogram, clinical laboratory tests (hematology, blood chemistry, and urinalysis), and adverse events (AEs).

Results
=======

Demographics
------------

Forty-eight subjects were enrolled in this study, and one subject dropped out because of consent withdrawal. The remaining 47 subjects completed the study as planned and were included in the PK analysis set. The mean ± standard deviation values of the demographic characteristics of the enrolled subjects were as follows: age, 24.44 ± 1.63 years; height, 175.98 ± 6.60 cm; and body weight, 64.94 ± 8.54 kg. There were no statistically significant differences in demographic characteristics between six-sequence groups ([Table S1](#SD1-dddt-12-1413){ref-type="supplementary-material"}).

PK results
----------

### PK characteristics of levodropropizine CR formulation

The AUC~0--24h~, which represents the total daily exposure, was similar for both formulations ([Table 1](#t1-dddt-12-1413){ref-type="table"}). The GMR and 90% CI for the AUC~0--24h~ of levodropropizine CR to IR were within the conventional bioequivalence range. Levodropropizine CR showed delayed *T*~max~, prolonged *t*~1/2~, and lower *C*~max~ compared to that of levodropropizine IR ([Figure 2](#f2-dddt-12-1413){ref-type="fig"}, [Tables 1](#t1-dddt-12-1413){ref-type="table"} and [2](#t2-dddt-12-1413){ref-type="table"}). The median *T*~max~ values were 1.00 and 0.75 h, the mean *t*~1/2~ values were 3.10 and 2.30 h, and the mean *C*~max~ values during 24 h were 261.22 and 325.46 μg/L for levodropropizine CR and IR, respectively. The GMRs and 90% CIs for the *C*~max~ and dose-normalized AUC~0--tau~ of levodropropizine CR to IR were within the conventional bioequivalence range after the first single dose administration ([Table 2](#t2-dddt-12-1413){ref-type="table"}). Individual comparisons of the *C*~max~ and AUC~0--24h~ between levodropropizine CR and IR are shown in [Figure 3](#f3-dddt-12-1413){ref-type="fig"}.

### Food effect on levodropropizine CR

The total exposure and peak concentration of levodropropizine CR were similar in both the fasted and fed groups. The GMRs and 90% CIs for the *C*~max~ and AUC~0--24h~ of levodropropizine CR fed to the fasted groups were within the conventional bioequivalence range ([Table 1](#t1-dddt-12-1413){ref-type="table"}). In addition, the GMRs and 90% CIs for the *C*~max~ and dose-normalized AUC~0--tau~ of levodropropizine CR fed to the fasted groups were within the conventional bioequivalence acceptance range ([Table 2](#t2-dddt-12-1413){ref-type="table"}). The fed group showed delayed absorption compared to the fasted group, and the median *T*~max~ values were 3.00 and 1.00 h, respectively ([Figure 4](#f4-dddt-12-1413){ref-type="fig"} and [Table 2](#t2-dddt-12-1413){ref-type="table"}). Individual comparisons of the *C*~max~ and AUC~0--24h~ are shown in [Figure 5](#f5-dddt-12-1413){ref-type="fig"}.

Tolerability assessment
-----------------------

Sixteen AEs occurred in 14 subjects. Of these, five AEs were observed in the levodropropizine IR 60 mg group, and 11 in the levodropropizine CR 90 mg group. All AEs were mild in severity, except for one subject who experienced urticaria after test drug. The AEs that occurred in the levodropropizine CR 90 mg group were the foreign body, dizziness, headache, presyncope, and abrasion. In the levodropropizine IR 60 mg group, diarrhea, rash pustular, pain in extremity, dizziness, headache, pyuria, contusion, dermatitis atopic, pruritus, and urticaria occurred as AEs. Of these, dizziness, headache, and diarrhea were reported as frequent AEs of levodropropizine on the drug label. No serious AEs occurred in either levodropropizine CR or IR administrated group. In addition, there were no clinically significant changes from the baseline of vital signs, physical examinations, electrocardiogram, and clinical laboratory tests in all subjects.

Discussion
==========

In this study, we aimed to compare the total daily exposure to levodropropizine CR and IR formulations at equal total daily dose of levodropropizine. Therefore, we measured the *C*~max~ and AUC~0--24h~ as primary PK parameters to compare the PK characteristics of the two formulations. In addition, we calculated the single-dose PK parameters to compare the absorption and elimination profiles of the different formulations.

This study showed that at equal total daily dose, the total daily systemic exposure to levodropropizine was comparable between the CR and IR formulations. The GMR (90% CI) of AUC~0--24h~ was 0.89 (0.86--0.93) although the GMR (90% CI) of *C*~max~ was 0.80 (0.75--0.85). The PK differences between the 90 mg CR and 60 mg IR tablets might not be clinically significant if the efficacy of levodropropizine is dependent on the total daily systemic exposure. Based on the results of a previous study, the onset of cough inhibitory action of levodropropizine was 1 h post-dose.[@b14-dddt-12-1413] Therefore, a minimal delay in *T*~max~ with the CR formulation would be clinically insignificant regarding the onset time of levodropropizine action. Further clinical study will be needed to evaluate the efficacy and safety of the CR formulation compared to the IR formulation.

The US Food and Drug Administration guidance recommends conducting a food-effect study to evaluate the bioavailability of modified-release formulations.[@b9-dddt-12-1413] This is because food can affect the PK of drug in various ways. In this study, food delayed the *T*~max~ of levodropropizine CR formulation. This could be attributed to alteration of the gastric pH because of food intake. For instance, weakly basic drugs, such as levodropropizine (p*K*~a1~=7.12 and p*K*~a2~=10.58), generally exhibit reduced dissolution at high pH.[@b7-dddt-12-1413],[@b15-dddt-12-1413],[@b16-dddt-12-1413] Because the gastric pH can easily increase by food intake, this can result in decreased absorption rate of weakly basic drugs. In addition, food delays the gastric emptying time, which leads to delayed oral absorption of drugs.[@b17-dddt-12-1413] Moreover, food can affect the action of hydroxypropyl methylcellulose (HPMC), which constitutes the matrix that modulates the drug release. For example, HPMC release was more rapid when the pH condition was similar to the fasted state of the stomach. However, when the pH increased from 1.20 to 6.80, it showed slow dissolution. Since the pH of the stomach after food intake is ∼4.90, HPMC would dissolve faster in the fasted state compared to that in the fed state.[@b18-dddt-12-1413] These mechanisms might contribute to the delay in *T*~max~ of levodropropizine CR when it was administered in the fed state. However, the GMRs and 90% CIs of the *C*~max~ and AUC~0--24h~ were within the conventional bioequivalence range; thus, the effect of food on the bioavailability of levodropropizine CR would be minimal.

Conclusion
==========

The total systemic exposure to levodropropizine was comparable between the CR and IR formulations in terms of the AUC. Although food delayed the absorption of levodropropizine CR, systemic exposure was not affected. Both levodropropizine CR and IR formulations were well tolerated in healthy subjects.

Supplementary material
======================

###### 

Baseline demographic characteristics of each sequence

  Characteristics   Sequence A (n=8)   Sequence B (n=8)   Sequence C (n=8)   Sequence D (n=8)   Sequence E (n=8)   Sequence F (n=8)   *p*-value
  ----------------- ------------------ ------------------ ------------------ ------------------ ------------------ ------------------ -----------
  Age (years)       24.13 ± 1.64       24.75 ± 1.67       23.50 ± 1.51       24.38 ± 1.92       24.50 ± 2.07       23.88 ± 1.89       0.7678
  Height (cm)       171.38 ± 6.99      177.38 ± 5.45      176.75 ± 6.67      173.88 ± 5.94      175.63 ± 5.73      180.88 ± 6.47      0.0776
  Weight (kg)       65.53 ± 8.94       66.45 ± 8.09       66.78 ± 6.37       62.70 ± 3.94       67.65 ± 5.74       73.80 ± 6.80       0.0609
  BMI (kg/m^2^)     22.23 ± 1.73       21.06 ± 1.69       21.37 ± 1.60       20.81 ± 2.12       21.93 ± 1.55       22.52 ± 1.19       0.2732

**Note:** Data are presented as arithmetic mean ± standard deviation.

**Abbreviation:** BMI, body mass index.
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![Schematic diagram of the study treatments and disposition of subjects.\
**Notes:** Reference, levodropropizine 60 mg IR tablet was administered three times daily with 6-h intervals in the fasted state. Test, levodropropizine 90 mg CR tablet was administered two times with 12-h interval in the fasted and fed states. All subjects were administered a total daily dose of 180 mg levodropropizine during the study period.\
**Abbreviations:** IR, immediate-release; CR, controlled-release.](dddt-12-1413Fig1){#f1-dddt-12-1413}

![Mean plasma concentration--time profiles of levodropropizine (**A**) in linear scale and (**B**) in log scale following administration of levodropropizine CR 90 mg and IR 60 mg under the fasted state.\
**Notes:** Bars represent standard deviations. Levodropropizine CR was administered twice with 12-h interval, and levodropropizine IR was administered three times with 6-h intervals.\
**Abbreviations:** CR, controlled-release; IR, immediate-release.](dddt-12-1413Fig2){#f2-dddt-12-1413}

![Individual comparisons of (**A**) *C*~max~ and (**B**) AUC~0--24h~ between the test and reference drugs in the fasted state.\
**Notes:** Subjects received the reference drug three times with 6-h intervals under the fasted state, and received the test drug two times with 12-h interval under the fasted state. Test drug, levodropropizine CR 90 mg; reference drug, levodropropizine IR 60 mg; *C*~max~, maximum plasma concentration; AUC~0--24h~, area under the concentration--time curve from the 0 to 24 h time point.\
**Abbreviations:** CR, controlled-release; IR, immediate-release.](dddt-12-1413Fig3){#f3-dddt-12-1413}

![Mean plasma concentration--time profiles of levodropropizine (**A**) in linear scale and (**B**) in log scale following administration of levodropropizine CR 90 mg in the fasted and fed states.\
**Notes:** Bars represent standard deviations. Levodropropizine CR was administered two times with 12-h interval.\
**Abbreviation:** CR, controlled-release.](dddt-12-1413Fig4){#f4-dddt-12-1413}

![Individual comparisons of (**A**) *C*~max~ and (**B**) AUC~0--24h~ of the test drug under the fasted and fed states.\
**Notes:** Subjects received the test drug two times with 12-h interval either in the fasted state or in the fed state. Test drug, levodropropizine CR 90 mg; *C*~max~, maximum plasma concentration; AUC~0--24h~, area under the concentration--time curve from the 0 to 24 h time point.\
**Abbreviation:** CR, controlled-release.](dddt-12-1413Fig5){#f5-dddt-12-1413}

###### 

*C*~max~ and AUC~0--24h~ of levodropropizine in each treatment regimen

  Pharmacokinetic parameters   Levodropropizine IR 60 mg   Levodropropizine CR 90 mg   Geometric mean ratio                       
  ---------------------------- --------------------------- --------------------------- ---------------------- ------------------- -------------------
  *C*~max~ (μg/L)              325.46 ± 104.51             261.22 ± 86.18              237.54 ± 87.59         0.80 (0.75--0.85)   0.90 (0.85--0.97)
  AUC~0--24h~ (h·μg/L)         2,807.73 ± 1,247.77         2,548.90 ± 1,182.66         2,712.34 ± 1,135.10    0.89 (0.86--0.93)   1.10 (1.05--1.14)

**Notes:** Data are presented as arithmetic mean ± standard deviation. *C*~max~, maximum drug concentration; AUC~0--24h~, area under the concentration--time curve from the 0 to 24 h time point.

**Abbreviations:** IR, immediate-release; CR, controlled-release; 90% CI, 90% confidence interval.

###### 

Single-dose PK parameters of levodropropizine

  Pharmacokinetic parameter   Levodropropizine IR 60 mg   Levodropropizine CR 90 mg   Geometric mean ratio                       
  --------------------------- --------------------------- --------------------------- ---------------------- ------------------- -------------------
  *T*~max~ (h)                0.75 \[0.25--2.00\]         1.00 \[0.25--4.00\]         3.00 \[0.25--6.00\]    --                  --
  *C*~max~ (μg/L)             278.14 ± 100.95             247.99 ± 81.63              225.46 ± 84.27         0.89 (0.84--0.95)   0.89 (0.84--0.95)
  AUC~0--tau~ (h·μg/L)        774.32 ± 302.52             1,229.20 ± 543.16           1,292.76 ± 545.98      --                  --
  AUC~0--tau~/D (h·μg/L/mg)   12.91 ± 5.04                13.66 ± 6.04                14.36 ± 6.07           1.02 (0.98--1.07)   1.07 (1.03--1.11)
  AUC~inf~ (h·μg/L)           969.06 ± 434.06             1,371.47 ± 688.30           1,473.83 ± 657.09      --                  --
  AUC~inf~/D (h·μg/L/mg)      16.15 ± 7.23                15.24 ± 7.65                16.38 ± 7.30           0.92 (0.88--0.95)   1.10 (1.05--1.15)
  *t*~1/2~ (h)                2.30 ± 0.55                 3.10 ± 0.85                 2.85 ± 0.90            --                  --
  CL/F (L/h)                  75.36 ± 33.91               84.61 ± 45.10               74.14 ± 33.94          --                  --

**Notes:** Data are presented as arithmetic mean ± standard deviation, except for *T*~max~ that is expressed as the median \[minimum--maximum\]. *C*~max~, maximum plasma concentration; *T*~max~, time to reach *C*~max~; AUC~0--tau~, area under the concentration--time curve from 0 to dose interval time; AUC~0--tau~/D, dose-normalized AUC~0--tau~; AUC~inf~, AUC from 0 to infinity; AUC~inf~/D, dose-normalized AUC~inf~; *t*~1/2~, half-life; CL/F, apparent clearance.

**Abbreviations:** PK, pharmacokinetic; IR, immediate-release; CR, controlled-release; 90% CI, 90% confidence interval.
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